Investment news

TruDiagnostic and NADMED partner on new NAD blood diagnostic

Using novel test, US healthcare providers can test patients’ NAD+ levels at home or in the clinic. Doctors in the US can now access a novel NAD+ blood diagnostic for…

Longevity investment bulletin: Celmatix, BlueRock, TruDiagnostic and more

The latest longevity updates from our investment news desk.  Celmatix unveils largest endometriosis study Ovarian longevity company Celmatix announced findings from its long-term collaboration to decode the genetic basis of…

Retro: A longevity biotech triple-threat?

Joe Betts-LaCroix on investing in longevity biotech and Retro’s progress in cellular reprogramming, autophagy and plasma programs. When longevity-focused decentralized science platform VitaDAO recently announced its latest funding round, one…

Cyclarity: When bad guy cells have a change of heart

How Cyclarity is targeting atherosclerosis and giving the body the means to reverse disease from the inside out. Atherosclerosis is a killer, and while the risk factors can be lowered…

Stressed tissue and cellular burn-out? Enter the Mitochondrial Cycle

Mitrix Bio CEO and Founder on mitochondrial degradation – and how it drives aging and lifespan. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company…

Cambrian Bio reveals new pipeline company with focus on AMPK activation

Amplifier Therapeutics is going after “one of the most sought-after drug targets in aging research”. Cambrian Bio, a clinical-stage biotech focused on treating and preventing chronic diseases of aging, has…

Longevity investment bulletin: Remedium Bio, GenSight Biologics, SomaLogic and more

The latest longevity updates from our investment news desk.  Remedium publishes gene therapy safety data Gene therapy company Remedium Bio announced the publication of pre-clinical data demonstrating the safety and…

First longevity clinical study design fetches FDA approval

New tricks: Loyal’s companion dog longevity study receives FDA protocol concurrence. Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs, has announced…

Longevity investment bulletin: ChromaDex, Nightingale Health, Capsida and more

The latest longevity updates from our investment news desk.   ChromaDex reports ‘best quarter ever’ Healthy aging supplements company ChromaDex (NASDAQ: CDXC) announced its fourth quarter and fiscal year 2022…